Apr 17, 2020

Toward a single dose cure for Buruli ulcer

BioRxiv : the Preprint Server for Biology
S. ThomasKevin Pethe


A single dose of TELACEBEC (Q203), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks post treatment. Clinical use of Q203 could dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.

  • References
  • Citations


  • We're still populating references for this paper, please check back later.
  • References
  • Citations


  • This paper may not have been cited yet.

Mentioned in this Paper

Metabolic Process, Cellular
Russula archaea
Prokaryotic potassium channel

Related Feeds


Recent advances in genomic sequencing has led to the discovery of new strains of Archaea and shed light on their evolutionary history. Discover the latest research on Archaeogenetics here.

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

Related Papers

Zeitschrift für Tropenmedizin und Parasitologie
G KieningerU Ullmann
Relevé épidémiologique Hebdomadaire
Journal of Advanced Nursing
Journal of the Indian Medical Association
E M EndeleyR V Patel
British Medical Journal
D E Ward
© 2020 Meta ULC. All rights reserved